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BACKGROUND: In the preceding decade, various studies on glioblastoma (Gb) demonstrated that signatures obtained from gene
expression microarrays correlate better with survival than with histopathological classification. However, there is not a universal
consensus formula to predict patient survival.
METHODS: We developed a gene signature using the expression profile of 47 Gbs through an unsupervised procedure and two
groups were obtained. Subsequent to a training procedure through leave-one-out cross-validation, we fitted a discriminant (linear
discriminant analysis (LDA)) equation using the four most discriminant probesets. This was repeated for two other published
signatures and the performance of LDA equations was evaluated on an independent test set, which contained status of IDH1
mutation, EGFR amplification, MGMT methylation and gene VEGF expression, among other clinical and molecular information.
RESULTS: The unsupervised local signature was composed of 69 probesets and clearly defined two Gb groups, which would agree with
primary and secondary Gbs. This hypothesis was confirmed by predicting cases from the independent data set using the equations
developed by us. The high survival group predicted by equations based on our local and one of the published signatures contained a
significantly higher percentage of cases displaying IDH1 mutation and non-amplification of EGFR. In contrast, only the equation based
on the published signature showed in the poor survival group a significant high percentage of cases displaying a hypothesised
methylation of MGMT gene promoter and overexpression of gene VEGF.
CONCLUSION: We have produced a robust equation to confidently discriminate Gb subtypes based in the normalised expression level
of only four genes.
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Glioblastoma (Gb) (grade IV glioma) is the most malignant form
of human brain tumour (Kleihues and Cavenee, 2000). Even that
the incidence of this cancer is low compared with other human
cancers (Louis et al, 2007), the fatal outcome associated with
its diagnosis has motivated in the past years intensive research
in its molecular transcriptomic profile. This previous work
demonstrated that molecular (or gene) signatures obtained from
microarray experiments allow a better characterisation of the
pathology than the current clinical scheme based on histopatho-
logical classification (Nutt et al, 2003; Freije et al, 2004; Phillips
et al, 2006). That is, molecular signatures are a better predictor of
the patient survival time than the diagnosis provided by histo-
pathology. Nutt and Freije in their respective works showed that
there may be two main groups with differential survival time: one
composed of anaplastic gliomas (grade III) and Gbs (grade IV),
and another one almost fully composed of Gbs. Later on, Phillips
et al (2006) also showed that glial tumours can be molecularly
divided into three different profiles: proneural, mesenchymal and
proliferative. The validity of these profiles was evaluated on a
larger data set composed of Gbs from various hospitals and
different types of Affymetrix microarrays (Lee et al, 2008).
However, Lee and collaborators found that only the proneural
profile patients displayed a longer survival time compared with the
rest of molecular groups. On the other hand, a prognosis predictor
was proposed to identify mesenchymal and proneural-like Gbs
based on the low or high expression of nine genes, respectively
(Colman et al, 2010). This body of molecular phenotyping work
has contributed to generate an eventual consensus around the
hypothetical distinction of gliomas based on these three profiles
mentioned (proneural, mesenchymal and proliferative). In parallel,
these profiles have been related to the type of stem cells from
which Gbs may arise (Beier et al, 2007; Gu¨nther et al, 2008;
Liu et al, 2009; Lottaz et al, 2010). Moreover, Gb cases showing
mutation of a specific locus of IDH1 and non-amplification of
EGFR gene have been related to a better prognosis (Parsons et al,
2008; Gravendeel et al, 2009; Yan et al, 2009; Verhaak et al, 2010).
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All these findings provide hope that prognosis of Gbs may be
improved based on the molecular features. However, a consensus
molecular signature that incorporates all these different findings
into an improved predictor to discriminate Gbs with respect to
prognosis (i.e., survival) is still lacking. To achieve this goal,
microarray data from various centres should be combined,
different data sets should be used to develop the molecular
signature and the outcome should be validated with an indepen-
dent data set, ideally from a different centre (Altman and Royston,
2000; Dupuy and Simon, 2007). Three previous studies partially
fulfilled these criteria considering data from various centres (Lee
et al, 2008; Colman et al, 2010; Lottaz et al, 2010), but only Colman
and collaborators validated their results using an independent test
set. In fact, they classified cases based on their proposed signature
and demonstrated that such a classification resulted into two
groups with differential survival. However, they did not estimate
the prediction ability of their signature through a leave-one-out
cross-validation (LOOCV) or by classification of cases from an
independent test set through a discriminant equation, as various
authors performed to molecularly distinguish high-grade gliomas
(Nutt et al, 2003; Petalidis et al, 2008; Li et al, 2009; de Tayrac et al,
2011). The absence of such estimation may cause problems for
other groups to predict new local Gb cases based on these
signatures. Verhaak et al (2010) validated their results on an
independent data set, but the rule used to classify new cases was
based on a signature composed of 840 genes. Although this is a
valid method to classify new cases, the large amount of genes
required excludes the possibility of developing a discriminant
linear equation due to colinearity problems and would complicate
the implementation on day-to-day diagnostic protocols.
Accordingly, the purpose of our study was first to produce a
probeset-based equation, as we already performed in two previous
works for a different problem (Castells et al, 2009, 2010), that could
distinguish Gb subgroups. Second, to assess the performance of
our local equation, we generated another probeset-based equation
using the gene signatures proposed by Lee and Colman in their
respective works (Lee et al, 2008; Colman et al, 2010). The
differential status of IDH1 mutation and EGFR amplification
found between groups stratified by our local signature-based
equation (LocSBE) and Colman signature-based equation
(ColSBE), suggests that the two groups of Gbs identified here
may correspond to the classical primary and secondary Gbs.
However, only ColSBE provided two groups that displayed a
significant survival difference, as well as a differential percentage
of cases showing both expected methylation of gene MGMT
promoter and overexpression of gene VEGF.
MATERIALS AND METHODS
Collection, storage and histopathology analysis of
prospectively acquired samples
Collection of biopsies was carried out at different hospitals from
the Barcelona metropolitan area through the European Union-
funded eTUMOUR (http://www.etumour.net) and HealthAgents
(Gonza´lez-Ve´lez et al, 2007) projects and the Spanish-funded
MEDIVO2 project.
A total of 44 biopsies were collected from the Hospital
Universitari de Bellvitge (L’Hospitalet de Llobregat), two biopsies
from the Hospital Universitari Germans Trias i Pujol (Badalona)
and one biopsy from the Hospital Sant Joan de De´u (Esplugues
de Llobregat). Among the 47 biopsies included in this study,
46 were Gbs and 1 was gliosarcoma, and their diagnosis was
directly obtained from the Histopathology ward of the partici-
pating hospitals (local data set from now on). The full study
protocol was approved by the local Ethics Committees and
informed consent was obtained from all patients.
An aliquot of tumour was snap frozen in liquid nitrogen until
RNA isolation. Another aliquot was fixed in 4% buffered formalin
and embedded in paraffin. For routine histological examination,
4-mm thick sections were stained with haematoxylin and eosin
(H&E). Both, the WHO 2000 and 2007 Nervous System Classification
criteria (Kleihues and Cavenee, 2000; Louis et al, 2007) were used for
diagnosis, since biopsies were collected from 2004 until 2008.
RNA isolation
Total RNA from frozen biopsies stored in liquid nitrogen was
isolated following the procedure indicated by the manufacturer
using the mirVana RNA isolation kit (Ambion-Life Technologies,
Grand Island, NY, USA). RNA was characterised using a NanoDrop
spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA). Absence of protein contamination was monitored by the
260/280 nm ratio of absorbance, and samples with a ratio ranging
between 1.6 and 2.0 were accepted for further processing. Integrity
of the RNA was assessed by using the capillary electrophoretic
system 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Only
samples producing a 28S/18S ratio equal or higher than 1.2 or an
RNA integrity number (RIN) number equal or higher than 6 were
used for further analysis. This was as agreed in the consensus
protocols for data acquisition in the eTUMOUR project.
Microchips and real-time PCR (RT–PCR)
Labelling and hybridisation onto microchips was performed at
the Affymetrix core facility of the Institut de Recerca de la Vall
d’Hebron (Barcelona). Labelling was performed using the One-
Cycle Target Labelling and Control Reagents kit (Affymetrix,
Santa Clara, CA, USA). The starting material for the labelling
protocol ranged from 1.5 to 5 mg of total RNA and the
resulting labelled cRNAs were hybridised onto the HG-U133 plus
2.0 GeneChip (Affymetrix). Fluorescence images were obtained by
scanning the microchips with the software provided with the
GeneChip Scanner 3000.
We used a two-step procedure for the RT–PCR experiments.
One microgram of total RNA was used for retrotranscription using
the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA).
A 1/20 dilution of the obtained cDNA was used for amplification with
the SsoAdvanced SYBR Green supermix on the CFX96 Real-Time
System (Bio-Rad). We analysed the expression of four genes using
specific primers designed by us: CHI3L1 (forward-CTGTGGGGA
TAGTGAGGCAT, reverse-TAGGATGTTTGGCTCCTTGG), LDHA
(forward-CACAGCTATATCCTGATGCTGG, reverse-GACTAGGCA
TGTTCAGTGAAGGAG), LGALS1 (forward-CTAAGAGCTTCGTGC
TGAACCTG, reverse-ATGCACACCTCTGCAACACTTC) and IGFBP3
(forward-AGGGCACTCTGGGAACCTAT and reverse-CTCTCTGT
CCCTCCTACCCC). Five samples per Gb group were evaluated
and triplicates per each sample–gene pair were performed. Fold
changes were computed following a method based on the relative
difference between groups (Livak and Schmittgen, 2001).
Normalisation of data and acquisition of publicly available
data sets
All data considered in this work were normalised using the robust
multi-array average (RMA) method, which is available in the affy
package from the R software (Irizarry et al, 2003). We initially
used as a test data set the data made publicly available in the
work of Lee et al (2008) (Lee’s data set from now on, GSE13041,
Gene Expression Omnibus; http://www.ncbi.nlm.nih.gov/gds). We
selected for our study those 218 out of the 267 Gbs available that
were hybridised onto either the Affymetrix microchips HG-U133A
(n¼ 191) or HG-U133 plus 2.0 (n¼ 27), since the probeset
annotation of the remaining 49 Gbs (HG-U95 Av2) did not match
with the one from the other types of microchips. We evaluated two
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signatures: one composed of 377 probesets described in Lee’s work
(Lee’s signature, from now on), and a second one provided by
Colman and collaborators (Colman’s signature, from now on).
This signature was derived from 110 cases published in four
previous works (Nutt et al, 2003; Freije et al, 2004; Nigro et al,
2005; Phillips et al, 2006). Probeset identifiers of the 38 genes
proposed in Colman’s work were not provided, since the signature
was mainly evaluated using RT–PCR. For this reason, we used
those 36 matching genes in both HG-U133A and HG-U133 plus 2.0
microarrays, which corresponded to 63 probesets in both
microarray types. For the second part of the study, we used data
made publicly available by Gravendeel et al (2009), Gravendeel’s
data set from now on (GSE16011). Among available data sets
containing Gbs, uniquely this one provides a large number of cases
(n¼ 73) with survival and KPS data, as well as status of both IDH1
mutation and EGFR amplification. We used those 71 Gbs that had
survival time and living status available.
Feature selection for the unsupervised classification
We selected those 100 probesets with the highest coefficient of
variation (CV) and at least 30% of signals higher than 1000 a.u. of
fluorescence among Gbs from our local data set. Probesets from
each signature were used as input for a hierarchical cluster using
the default settings of the heatmap_2 function from the Heatplus R
package (R Development Core Team, 2011), but we used the
‘Manhattan’ distance and the ‘Ward’ clustering method, as
described in a previous work (Tortosa et al, 2011). In doing so,
we obtained a heatmap with probesets grouped in rows and cases
in columns. Those cases that were clustered together in a given
branch were assigned to one group of Gbs. The optimal number of
groups of Gbs was determined using the k-means method by
setting the number of clusters to 2, 3, 4 or 5. The reliability of such
clusters was assessed through the computation of the silhouette
statistic from the cluster R package (Hartigan and Wong, 1979).
The closest to 1, the highest the dissimilarity between clusters of
cases is (Rousseeuw, 1987). For our unsupervised signature, the
expression difference between groups of Gbs was assessed by
computing the q-value for all probesets in our local data set (Storey
and Tibshirani, 2003). We provide a graphical summary of this
section in Supplementary File 1A. An overview of this and next
sections is depicted in Figure 1.
Survival analysis
Analyses described in this section were performed using the
default settings of the survival package from the R software
(R Development Core Team, 2011). We fitted a survival curve for
each molecular group of Gbs using the Kaplan–Meier estimate
(function survfit). We included in this analysis either patients for
which the date of death was recorded or those patients alive, but
for whom a follow-up time of at least half a year was recorded. The
difference between the fitted Kaplan–Meier curves was assessed
using the Mantel–Haenszel test (function survdiff) (Harrington
and Fleming, 1982). A description of survival data is provided in
Supplementary Table 1.
On the other hand, we fitted a Cox’s proportional hazards model
(function coxph) using Gravendeel’s data set (Supplementary
Table 6). Models were fitted using as a factor the Gb group
provided by the four probeset-based equation that detected the
highest survival difference on Gravendeel’s data set. However, we
also fitted a Cox’s proportional hazards model in Gravendeel’s data
set for the variables IDH1 and EGFR status, LOH of chromosomes
1p and 19q, age, gender, administration of chemotherapy and
radiotherapy, surgery type, and KPS. In contrast, we fitted a Cox’s
proportional hazards model in Lee’s data set for the same variables
than before, except KPS and IDH1 and EGFR status, but we
included the Gb group as assigned by Lee and collaborators, status
expression of genes MGMT, VEGF and EGFR, and complementary
administration of temodar (Supplementary Table 6). Therapy-
related variables (chemotherapy, radiotherapy and temodar)
in Lee’s data set and radiotherapy administered in Gravendeel’s
data set only indicated those patients subjected to the therapy.
The rest of the values were missing and we assumed that
those missing values corresponded to patients not subjected to
therapy. The significance of each variable was assessed using
Wald’s test and the 95% confidence intervals for the hazard ratio
were reported.
Evaluation of the predictive ability of gene signatures on
the local data set
We considered three signatures in this work: (1) our local
unsupervised signature, (2) Lee’s signature and (3) Colman’s
signature, as described above. We tested the predictive ability of
these signatures by performing an LOOCV on our local data set.
We standardised the expression values using the mean and
standard deviation of each probeset, and assigned the group to
each sample by performing a hierarchical cluster, as previously
explained. The grouping provided by the hierarchical cluster was
considered as the ‘gold-standard’ for classification purposes in
this and next section. For each gene signature evaluated, we
selected those four probesets with the highest fold change among
differentially expressed genes (P-valueo0.05, Wilcoxon rank-
based test after Bonferroni correction) among training samples
(all except the sample left out). At each iteration, these probesets
were used to calculate a linear discriminant analysis (LDA)-
based formula using the lda function from the R package MASS
(R Development Core Team, 2011). This function produced an
additive model composed of four variables (four probesets), each
one with a discriminant coefficient. We predicted the group of
the case left out from the training set by using the discrimi-
nant scores, which we obtained by multiplying the discriminant
coefficients from the lda function and the standardised expres-
sion values of each probeset. The discriminant threshold used
was 0, since this value is the expected centroid between the two
groups by using this approach. We repeated this procedure as
many times as cases were available in the data set. In case there
were no probesets below the Bonferroni threshold, we selected
those four probesets that displayed the highest fold changes.
We saved the name of the four probesets selected at each
iteration, so that we could summarise the most discriminant
ones. Accuracy, sensitivity and specificity were computed from
test sample results. We provide a graphical summary of this
section in Supplementary File 1B.
Development of a predictive equation
Considering that the predictive ability of each formula was going
to be initially tested on Lee’s data set, we standardised the
expression values of our local and Lee’s data set using the mean
and standard deviation of Lee’s data set, as we previously
described (Castells et al, 2010). We reassigned the group of cases
(both local and Lee’s data sets) through hierarchical clustering
using the four most relevant probesets from each signature.
We generated a discriminant formula only using our local data
set and the four most frequently selected probesets across the
LOOCV, with highest fold change and the lowest P-value. This
equation was used to predict the group of each case from Lee’s
data set as described in the previous section. Accuracy, sensitivity
and specificity obtained from Lee’s data set were considered as
the estimated predictive ability of each discriminant formula.
We provide a graphical summary of this section in Supplementary
File 1C. The discriminant ability of equations generated was tested
using Gravendeel’s data set. The difference between the percentage
of cases showing both IDH1 mutation and non-amplification of
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EGFR in each Gb subtype was assessed using Pearson’s w2-test and
considered significant for a P-value under 0.05. Other molecular
and clinical variables (LOH of chromosomes 1p and 19q, therapy,
age, gender and KPS) were also evaluated (Supplementary
Figures). Similarly, Lee’s data set was used to evaluate the
performance of equations on clinical (collection centre, therapy,
age and gender) and molecular (expression of genes MGMT,
VEGF and EGFR, and molecular cluster) variables available.
As for Cox’s models, we assumed no therapy administered
for those cases showing missing values in therapy variables
(chemotherapy, radiotherapy and temodar). In Supplemen-
tary Figures, difference between groups for numeric variables
(age and KPS) was assessed using a t-test and considered
significant for a P-value under 0.05.
RESULTS
Unsupervised analysis to detect molecular subgroups of Gb
Our unsupervised signature composed of 100 probesets obtained
the highest values of the silhouette statistic when we set the
number of k-means clusters to two (silhouette¼ 0.26). However,
not all 100 probesets selected were differentially expressed between
the two potential molecular groups of Gb (Supplementary Table 2).
For this reason, we selected those 69 probesets that were
differentially expressed (q-valueo0.05) between the molecular
subgroups and repeated the hierarchical cluster, as well as the
computation of the silhouette statistic. These 69 probesets resulted
in an increased value of the silhouette statistic compared with the
Local data set
47 Gbs
Probeset
selection
Lee’s data set
218 Gbs
Gravendeel’s data set
71 Gbs
Local signature
69 probesets
Lee’s signature
377 probesets
Colman’s signature
63 probesets Standar-disation
Standar-
disation
HC
HC
LOOCV
LDA
Survival
analysis
Standar-
disation
4 Discriminant
probesetsHC
: OR
IDH1/EGFR
alterations
HC
Standardisation
Lee’s values
LocSBE
LDA
equation
Estimated
prediction LeeSBE
ColSBE
Figure 1 Diagram of analyses performed. This figure provides an overview on data analysis performed in this work. Computations are described inside
empty rhombus, data sets indicated inside a gridded box and groups of probesets depicted inside a grey box. Analyses downstream grey boxes were
performed separately for each signature (Local, Lee’s or Colman’s signatures). Standardisation Lee’s values denotes standardisation of local data set using
mean and standard deviation values from Lee’s data set. The estimated prediction indicated inside a circle filled with dots corresponds to the error obtained
by comparing classifications produced by hierarchical cluster and LDA equations. HC is an abbreviation for hierarchical cluster, LOOCV LDA means leave-
one-out cross-validation based on LDA, 4 discriminant probesets indicates that those four most discriminant probesets across LOOCV were selected and
IDH1/EGFR alterations corresponds to the percentage of cases showing IDH1 mutation/EGFR non-amplification per Gb group.
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previous signature regardless the number of k-means clusters
considered, while the optimal one was maintained at two clusters
(silhouette¼ 0.34).
The 69 probesets defined one group (group of low expression
(GLE) from now on, n¼ 14) of samples that displayed on average
low expression values (Figures 2A and B). This means that most
cases in GLE displayed lower expression values than the group of
high expression (GHE), but not all of them (Figure 2A).
Interestingly, a small difference in the average age of patients
between groups was found (GLE¼ 51.1±21.2 years and
GHE¼ 63.0±9.2 years, P-value¼ 0.078, Wilcoxon rank-based test;
Figure 2B). In contrast, neither our local signature detected two
groups displaying a different survival time (P-value¼ 0.826), nor
did Lee’s and Colman’s signatures (P-value¼ 0.729 and 0.461,
respectively; Figure 2B).
Moreover, some probesets represent genes that have been
related to glioma or Gb tumourigenesis: proliferative factors or
their receptor (EGR1, IGFBP2, IGFBP3 and VEGFA) (Zhang et al,
2002; Lo¨nn et al, 2008; Norden et al, 2009; Mittelbronn et al, 2009),
collagen isoforms (COL1A1, COL1A2 and COL3A1) (Kirsch et al,
2000; Rege et al, 2005), proteins that bind to fatty acids (FABP5
and FABP7) (Mita et al, 2007; Brun et al, 2009) and transmem-
brane proteins (CD24 and CD163) (Senner et al, 1999; Komohara
et al, 2008). Additionally, some genes that are overexpressed in
GHE (GBP1, SERPINA3, CD163, TIMP1, CHI3L1, IGFBP2 and
FABP5) were also detected by Tso et al (2006) overexpressed in
primary Gbs compared with low-grade gliomas. Also, our local
signature has 9 genes (11 probesets) in common with Colman’s
signature (CHI3L1, COL1A2, FABP5, GRIA2, IGFBP2, IGFBP3,
MAOB, NNMT and TIMP1), among which two of these were
included in the final signature proposed in their work. Six other
genes in our signature correspond to gene isoforms in Colman’s
signature (ACTA2, COL1A1, COL3A1, FABP7, SERPINA3 and
VEGFA). Similarly, 14 probesets of our local signature matched
with those in Lee’s signature (ACTA2, ADM, ANXA1, COL1A2,
COL3A1, CD163, DCN, IGFBP2, MGP, NNMT, TIMP1, RCAN1,
SERPINA3 and VEGFA).
Evaluation of the predictive capacity of gene signatures on
the local data set through LOOCV
The optimal number of case clusters was again two, as assessed by
silhouette values (Supplementary Table 3). We obtained the
prediction accuracy, the sensitivity and the specificity of GLE for
each gene signature. The best prediction in our data set (n¼ 47)
was produced by our local gene signature, the second one by
Colman’s signature and the third one by Lee’s signature
(Figure 2B). In fact, our local and Colman’s signatures displayed
a high percentage of probesets differentially expressed (below the
Bonferroni threshold) among those selected in the LOOCV
(Supplementary Table 4). In contrast, few probesets in Lee’s
signature were differentially expressed.
Local data set (n =47)
Local
69 probesets
Lee
377 probesets
Colman
36 genes
Intensity ± sd GHE (a.u.)  2163.1 ± 2165.6 457.7 ± 886.3 1398.6 ± 1899.8
Intensity ± sd GLE (a.u.)  920.6 ± 1081.7 179.6 ± 390.7 557.8 ± 923.4
P-value intensity  < 2.2E–16 < 2.2E–16 < 2.2E–16
% Females GHE  42.4 40.5 38.9
% Females GLE  28.6 30.0 36.3
P-value gender  0.572 0.809 1.000
Age ± sd GHE (years)  63.0 ± 9.2 61.9 ± 11.8 62.9 ± 11.8
Age ± sd GLE (years)  51.1 ± 21.2 50.0 ± 21.0 48.2 ± 18.5
P-value age  0.078 0.077 0.006
Accuracy (%)  93.6 87.3 91.5
Sensitivity GLE (%)  78.6 40.0 72.7
Specificity GLE (%)  100.0 100.0 97.2
P-value survival  0.826 0.729 0.461
# Cases GHE  33 37 36
# Cases GLE  14 10 11
Lee 2008 data set (n =218)
LocSBE LeeSBE ColSBE ConsSBE
Intensity ± sd GHE (a.u.)  1924.8 ± 1176.4 434.3 ± 534.8 3173.5 ± 2194.5
Intensity ± sd GLE (a.u.)  437.1 ± 512.6 345.7 ± 229.2 411.4 ± 372.1
P-value intensity  < 2.2E–16 0.008 < 2.2E–16
% Females GHE  32.7 36.6 37.2 
% Females GLE  42.0 56.3 54.5 
P-value gender  0.155 0.198 0.403 
Age ± sd GHE (years)  56.2 ± 12.1 54.1 ± 13.8 54.1 ± 13.6
Age ± sd GLE (years)  50.9 ± 14.6 45.3 ± 9.7 40.8 ± 7.7
P-value age  0.003 0.008 0.0004 
Accuracy (%)  83.5 61.5 68.3 
Sensitivity GLE (%)  86.0 100.0 100.0 
Specificity GLE (%)  80.8 58.4 66.7 
P-value survival  0.464 0.018 0.016 
# Cases GHE  104 202 207 
# Cases GLE  114 16 11 
−3 −2 −1 0 1 2 3
Group low
expression (GLE)
Group high
expression (GHE)
2474.8 ± 2645.9 
1175.8 ± 1538.7 
55.8 ± 11.4
52.0 ± 14.8
<2.2E–16
34.9
40.0
0.546
0.046
66.1
53.3
86.7
0.223
83
135
Figure 2 Summary of unsupervised and supervised analysis. (A) This figure displays the molecular profile of the 69 probesets with the highest CV and
with fluorescence signals higher than 1000 a.u. in at least 30% of cases. Also, these probesets are differentially expressed between the two groups of
glioblastomas and their expression values are independent from patient’s gender (see also Supplementary Table 1). Columns are Gb cases and rows
probesets. The bottom bar indicates the normalised intensity (arbitrary scale) of probesets per sample. (B) We depict the characteristics of groups (GHE
and GLE) detected for each gene signature tested on our local non-standardised data set. Three signatures were evaluated: (1) 69 probesets obtained
through our unsupervised approach, (2) Lee’s signature and (3) Colman’s signature, which corresponded to 63 probesets. (C) Features obtained by applying
each four probeset-based equation on Lee’s standardised data set. GHE means group of high expression and GLE means group of low expression.
Differences between groups in both intensity and age were tested using the Wilcoxon rank-based test, while Pearson’s w2-test was used to evaluate
differences in the gender ratio between groups.
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Development of discriminant equations
We selected among probesets used in the LOOCV those four ones
from each signature that fulfilled the criteria explained above. The
selected probesets were used to perform a hierarchical cluster to
assign group membership in Lee’s data set. We built the LDA
equation for each signature considering two groups, as indicated
by the silhouette statistic, which were called GHE and GLE. In fact,
only in Lee’s signature the difference of intensity between means
was overlapping and the least significant (see Figure 2C), but we
also set the GHE to the group with highest average value. The
resulting equations are
LocSBE¼  0:181SðCOL1A2 Þþ 1:421SðPOSTNÞ
 0:146SðNNMTÞþ 0:600SðDCNÞ ð1Þ
LeeSBE¼  0:182SðTIMP3Þþ 0:423SðHs:301281Þ
 0:581SðFAM64AÞ 0:815SðECT2Þ ð2Þ
ColSBE¼ 0:990SðCHI3L1Þþ 0:693SðLDHAÞ
þ 1:190SðLGALS1Þ 0:487SðIGFBP3Þ ð3Þ
LocSBE, LeeSBE and ColSBE represent discriminant scores from
Local, Lee or Colman-signature based equation, respectively, and
S(x) indicates standardised values of an x probeset of a given gene,
as listed in Supplementary Table 5. A negative DSC corresponds to
GLE, while a positive one to GHE. An example for the computation
of discriminant values for each case is described in Supplemen-
tary File 2. Detailed results of this section are provided in
Supplementary Tables 3–5.
As shown in Figure 2C, the significantly higher age of patients in
GHE compared with GLE in Lee’s data set, regardless the four
probeset-based signature used, seems to agree with the results for
primary Gbs provided by Tso et al (2006). Indeed, some of the
genes or similar isoforms that compose the four probeset-based
signatures (NNMT, CH13L1, IGFBP3, TIMP3 and COL1A2) were
overexpressed in GHE, as were overexpressed in primary Gbs
compared with low-grade gliomas (Tso et al, 2006). The highest
prediction accuracy for subtype membership was obtained by
our LocSBE (83.5%), while the other ones were far below in
performance (61.5% and 68.3% for LeeSBE and ColSBE signatures,
respectively). However, the groups distinguished by LocSBE did
not show a significant survival difference, whereas the LeeSBE and
ColSBE did (Figure 2C and Figures 3A–C). At this point, we
hypothesised that a consensus signature (ConsSBE) that included
the 12 probesets from the three four probeset-based signatures
could improve both the prediction accuracy and the detection of a
difference in survival, but such hypothesis failed (Figure 2C).
Prediction ability on an independent data set
We assigned the class group to cases from Gravendeel’s data set
using Equations 1–3 and evaluated in each Gb group the
percentage of individuals simultaneously showing IDH1 mutation
and non-amplification of EGFR. Both LocSBE and ColSBE
displayed a significantly higher percentage of cases with the
mentioned alterations in the GLE group compared with the GHE
one (Figure 3D). As previous work reported that secondary Gbs are
characterised by a higher accumulation of IDH1 mutation (Yan
et al, 2009), the use of LocSBE and ColSBE seems to distinguish
these two subtypes. However, only groups identified by ColSBE
displayed a differential survival (Figure 3G), whereas LocSBE
showed a mild non-significant difference and survival of groups
distinguished by LeeSBE was almost identical.
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Figure 3 Survival analysis and genetic alterations plots. (A–C) These figures depict survival plots using Lee’s data set and splitting cases using LocSBE,
LeeSBE and ColSBE, respectively. (D) We provide the percentage of cases harbouring both IDH1 mutation and non-amplification of EGFR in each Gb
subtype (GLE and GHE). (E–G) These figures depict the same than figures (A–C), but using Gravendeel’s data set.
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We evaluated the ability of ColSBE as a survival predictor
by fitting a proportional hazards Cox’s model (Table 1).
We confirmed that those individuals from GHE have almost three
times (or 277%) higher probability of death (hazard ratio) than
those ones from GLE using Gravendeel’s data set, while higher
than two using Lee’s data set. Similarly, the hazard ratio increased
almost three times (or 275%) for those patients not displaying
IDH1 mutation and almost halved (down to 55.8%) for those ones
showing EGFR amplification. Patients simultaneously harbouring
IDH1 mutation and EGFR non-amplification further reduced the
probability of death down to a 25.5%. In front of this result, we
tested whether those patients simultaneously harbouring IDH1
mutation, non-amplification of EGFR and classified as GLE by
ColSBE displayed a lower probability of death than the rest of
patients. This resulted into a decrease down to 16.1% of the death
hazard ratio, or inversely, more than six-fold increase of the death
hazard ratio for those patients not showing the above-mentioned
pattern for these three features. Cox’s models on Lee’s data set
showed that non-proneural cases have an 84.1% higher probability
of death than proneural ones. Also, the increase of one KPS unit
and radiotherapy administration resulted into a decrease in the
hazard ratio down to 95.1% and 50.1%, respectively. On the
contrary, each additional year of patient’s life provokes a 2.3%
increase of probability of death in Gravendeel’s data set and almost
the same percentage (2.5%) in Lee’s data set. None of the rest of
variables was a significant predictor of survival.
On the other hand, considering that probesets composing
ColSBE may have a potential diagnostic use, we validated their
expression in our local data set samples by RT–PCR. As we shown
in Table 2, fold changes between GLE and GHE were coherent with
the ones obtained using microarray data.
Composition of Gb groups
A complementary study of Cox’s models was performed by
analysing the composition of GHE and GLE in terms of available
variables in Lee’s and Gravendeel’s data sets. We evaluated the
percentage of cases from each profile (proneural, proliferative,
mixed proliferative-mesenchymal -promes- and mesenchymal)
within GHE and GLE. As we shown in Supplementary Figure 1, a
significant difference between GHE and GLE is observed,
regardless of the equation used to classify cases. However, almost
all GLE cases (10 out of 11) belonged to the proneural profile when
using ColSBE, while all profiles were represented using LocSBE
and only proliferative and promes using LeeSBE. This feature and
Table 1 Summary of Cox models
Variable Level Hazard ratio SE z P4z 95% CI
Gravendeel’s data set
ColSBE GHE 2.772 0.297 3.431 0.0006 1.548–4.963
IDH1/EGFR IDH1-yes/EGFR-not 0.255 0.404  3.382 0.0007 0.116–0.563
ColSBE/IDH1/EGFR GLE/IDH1-yes/EGFR-not 0.161 0.500  3.658 0.0002 0.060–0.428
IDH1 Wild-type 2.749 0.352 2.871 0.004 1.379–5.484
EGFR Wild-type 0.558 0.260  2.246 0.025 0.335–0.928
1p LOH 0.595 0.552  0.942 0.346 0.2015–1.754
19q LOH 1.005 0.464 0.01 0.992 0.405–2.496
Chemotherapy Administered 1.333 0.279 1.032 0.302 0.772–2.302
Radiotherapy Administered 0.501 0.323  2.142 0.032 0.266–0.943
Surgery Open biopsy 0.621 0.746  0.639 0.523 0.143–2.678
Partial resection 1.423 0.269 1.31 0.19 0.839–2.412
Stereotactic biopsy 0.984 0.549  0.03 0.976 0.335–2.887
Gender Male 1.133 0.269 0.462 0.644 0.668–1.919
Age Year 1.023 0.011 2.087 0.037 1.001–1.044
KPS Unit KPS 0.951 0.0089  5.64 1.7 10 8 0.934–0.968
Lee’s data set
ColSBE GHE 2.156 0.327 2.35 0.019 1.136–4.091
HC Non-proneural 1.841 0.164 3.712 0.0002 1.334–2.541
MGMT Overexpressed 1.321 0.142 1.953 0.051 0.999–1.746
VEGF Overexpressed 1.260 0.142 1.631 0.103 0.955–1.663
EGFR Overexpressed 0.993 0.166  0.045 0.964 0.717–1.374
Chemotherapy Administered 1.378 0.194 1.651 0.099 0.942–2.017
Radiotherapy Administered 1.294 0.189 1.363 0.173 0.893–1.875
Temodar Administered 1.507 0.227 1.804 0.071 0.965–2.353
Gender Male 1.069 0.145 0.457 0.648 0.804–1.421
Age Year 1.025 0.0054 4.532 5.8 10 6 1.014–1.035
Abbreviations: CI¼ confidence interval; ColSBE¼Colman signature-based equation; GHE¼ group of high expression; GLE¼ group of low expression; HC¼ hierarchical cluster;
KPS¼ Karnofsky Performance Status; LOH¼ loss of heterozygosity; SE¼ standard error. This table summarises Cox’s proportional hazard models fitted with different variables.
For each model, death hazard ratio’s variation with respect to the reference level of a given factor (ColSBE: GLE; IDH1/EGFR: any combination except IDH1 mutated/EGFR non-
amplification; ColSBE/IDH1/EGFR: GLE/IDH1 mutated/EGFR non-amplification; IDH1: IDH1 mutated; EGFR: EGFR amplification; 1p: non-LOH of 1p; 19q: non-LOH of 19q;
gender: female; chemotherapy, radiotherapy and temodar: untreated; HC: proneural, MGMT; VEGF and EGFR: non-overexpressed; non and Surgery: complete resection) or per
unit of a continuous variable (age and KPS) is indicated. Also, the SE, the z-value of Wald’s test, the associated P-value to the z-value (P4z) and the 95% CI are provided.
Table 2 Validation of microarray measurements using RT-PCR
Fold-change GHE/GLE
Gene symbol Probeset RT–PCR Microarrays
CHI3L1 209395_at 13.7 7.1
LDHA 200650_s_at 5.3 3.7
LGALS1 201105_at 6.7 5.6
IGFBP3 212143_s_at 8.5 10.6
Abbreviations: ColSBE¼Colman signature-based equation; Gb¼ glioblastoma;
GHE¼ group of high expression; GLE¼ group of low expression. This table
compares fold changes of the four probesets that fit the ColSBE measured by both
microarrays and RT–PCR. Fold changes of RT–PCR experiments are the average of
five cases per Gb group. Each pair sample–gene was measured by triplicate and their
corresponding Ct values were detected within a 0.5 range.
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the increased number of cases with low expression of gene MGMT
and VEGF (Supplementary Figure 2) further corroborates that
cases classified as GLE by ColSBE are expected to develop a less
malignant cancer. In this sense, most patients previously untreated
or non-complementarily treated with temodar were classified as
GLE (Supplementary Figure 3) by LeeSBE and ColSBE, but this
difference was not significant. Gender did not appear to display a
different representation between GHE and GLE, but a significant
decrease of patient’s age was observed in GLE cases regardless the
equation used (Supplementary Figure 4). The validity of results
based on ColSBE is also assessed by the statistically equal
distribution of collection centres in GHE and GLE, which is not
observed using the LocSBE and LeeSBE (Supplementary Figure 1).
Gravendeel’s data set allowed assessing the relevance of loss of
heterozygosis of chromosomes 1p and 19q, but not significant
difference was observed (Supplementary Figure 5). Inversely, the
separated analysis of IDH1 status and EGFR amplification
provided an equivalent result than considering simultaneous
alterations (Figure 3 and Supplementary Figure 5). Type of
surgical resection, radiotherapy and chemotherapy administered
did not display a significant percentage difference between GHE
and GLE, except the high percentage of patients subjected to
chemotherapy in GLE when using the LocSBE (Supplementary
Figure 6). The average age of patients was lower in GLE only when
the classification was based on ColSBE (Supplementary Figure 7),
which confirms the result observed using Lee’s data set. Never-
theless, neither gender, nor KPS appeared to be a differential
feature between GHE and GLE.
DISCUSSION
Extensive previous work has tried to uncover a molecular
signature, which can be used to improve diagnosis and prognosis
of high-grade gliomas and/or specifically Gbs. However, there is no
widely accepted and validated consensus equation yet to carry out
this discrimination for Gbs. For this reason, we followed a step-
wise approach in this work to generate discriminant equations.
Our local signature splits cases in two groups (GHE and GLE),
which agrees with the number of Gb groups found in Lee’s and
Colman’s works. Among genes overexpressed found by Tso and
collaborators in primary Gbs compared with low-grade gliomas,
only EGFR and SEC61G were not overexpressed in our GHE
compared with GLE group. In fact, the lack of overexpression of
EGFR and SEC61G in GHE could imply that these two genes are a
characteristic feature of Gbs in general, but not a differential
feature of primary Gbs. In this sense, the high expression of ADM
and FCGBP also shows that these genes could also be characteristic
of primary Gbs, although Tso and collaborators found over-
expression for both Gb subtypes.
Furthermore, the average age of patients in the GLE group was
lower than in GHE when evaluated on Lee’s data set. Both
molecular features and age of patients in each group seem to agree
with the results published by Tso et al (2006), which described
these features for primary and secondary Gbs. Thus, we may
hypothesise that GHE and GLE detected using our local signature
could correspond to primary and secondary Gbs, respectively.
Such hypothesis was confirmed when we applied the equations
generated on the fully independent data set made available by
Gravendeel and collaborators. The GLE assigned by LocSBE and
ColSBE displayed a significant higher percentage of Gbs harbour-
ing both IDH1 mutation and non-amplification of EGFR than GHE.
However, only ColSBE was able to distinguish two groups
displaying a significant survival difference.
In fact, the percentage of cases showing IDH1 mutation
in primary Gbs described by Yan and collaborators (6%) was
similar to the percentage of GHE cases detected by ColSBE in
Gravendeel’s data set, which displayed both IDH1 mutation and
non-amplification of EGFR (6.5%). This value is also similar
to the percentage of primary Gbs showing IDH1 mutation, as
described by Lai and collaborators. Thus, these features would
agree with what had already been described for primary Gbs
(Yan et al, 2009; Lai et al, 2011). Moreover, the percentage of
cases showing such alteration in GLE cases (44.4%) approached
the percentage of proneural cases with IDH1 mutated (30%),
as described by Verhaak et al (2010). Considering that only
proneural and neural cases showed IDH1 mutation in their
work and that GLE based on ColSBE showed a predominant
percentage of proneural cases, GLE-classified cases are expected
to display a better prognosis than GHE ones. This hypothesis
is also confirmed by the significant higher percentage of GLE
cases showing low expression of genes MGMT and VEGF,
although the expression status of these genes did not imply a
significant improvement of survival (Table 1).
In addition, ColSBE-based classification and IDH1/EGFR status
are predictors of survival as revealed by Cox models, but
stratification of patients by combining ColSBE and IDH1/EGFR
status was translated into the strongest decrease of death hazard
ratio among variables analysed. This result indicates that these
three molecular features do not exclude each other, but provide a
refined prediction of patient’s survival. In this sense, our and
previous work’s results suggest that an effort should be done to
establish a ‘gold-standard’ to classify newly acquired Gb biopsy
cases. Our proposed discriminant equation, together with IDH1/
EGFR status, provides a link between classical ‘primary’ and
‘secondary’ accumulated clinical information and an objective
molecular discrimination of those clinical entities.
Conversely, the high prediction accuracies obtained through
LOOCV suggest that in small data sets, class prediction may be
fairly optimal, regardless of the signature used. Nevertheless, the
prediction of Lee’s cases through a four probeset-based LDA
equation revealed a much higher prediction accuracy of our
LocSBE (83.5%), as compared with the other ones (61.5 and
68.3%). Comparing these results with the ones obtained from
survival analysis, it seems evident that our feature selection
method tends to select probesets more able to predict the class
group of test cases, rather than detecting differential survival
between Gb groups. This can be due to our feature selection
strategy that did not consider probesets highly correlated with
survival, which is a similar strategy to the one used by Li et al
(2009). In contrast, signatures obtained in Lee’s and Colman’s
works considered such correlation.
Then, our study proposes a strategy towards the establishment
of a ‘gold-standard’ for Gb subtyping. To our knowledge, there is
not a single equation available in the literature to directly predict
survival or subtype of Gb cases. Then, we have herewith produced
formulas (Equation 1–3) for each gene signature and fully
documented the postprocessing protocol for anyone to be able to
test their performance. Colman signature-based equation appears
to confidently distinguish Gbs with expected high survival and it
may differentiate the subtype of Gbs better than the clinical history
alone. That is, the classification of primary and secondary Gbs only
based in the recurrence of the glioma may be misleading, because
early clinical signs or symptoms may have been bypassed. This
would artefactually increase the primary Gb group based in clinical
history alone. Considering that confident identification of
primary/secondary Gb would have a diagnostic interest, but there
is no confident method for such a purpose (Ohgaki and Kleihues,
2007; Louis et al, 2007), we propose ColSBE as a diagnostic tool to
be tested in the day-to-day work at the (molecular) histopathology
laboratory, which used conjointly with evaluation of IDH1/EGFR
status may improve prediction of patient’s survival. The validation
of expression values from ColSBE through RT–PCR demonstrates
the potential diagnostic use of such equation, although we
recognise that further work is necessary to fit an LDA equation
solely based on RT–PCR values.
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